It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Development of distant metastasis is the main cause of deaths in prostate cancer (PCa) patients. Understanding the mechanism of PCa metastasis is of utmost importance to improve its prognosis. The role of exosomal long noncoding RNA (lncRNA) has been reported not yet fully understood in the metastasis of PCa. Here, we discovered an exosomal lncRNA HOXD-AS1 is upregulated in castration resistant prostate cancer (CRPC) cell line derived exosomes and serum exosomes from metastatic PCa patients, which correlated with its tissue expression. Further investigation confirmed exosomal HOXD-AS1 promotes prostate cancer cell metastasis in vitro and in vivo by inducing metastasis associated phenotype. Mechanistically exosomal HOXD-AS1 was internalized directly by PCa cells, acting as competing endogenous RNA (ceRNA) to modulate the miR-361-5p/FOXM1 axis, therefore promoting PCa metastasis. In addition, we found that serum exosomal HOXD-AS1 was upregulated in metastatic PCa patients, especially those with high volume disease. And it is correlated closely with Gleason Score, distant and nodal metastasis, Prostatic specific antigen (PSA) recurrence free survival, and progression free survival (PFS). This sheds a new insight into the regulation of PCa distant metastasis by exosomal HOXD-AS1 mediated miR-361-5p/FOXM1 axis, and provided a promising liquid biopsy biomarker to guide the detection and treatment of metastatic PCa.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 The 1st Affiliated Hospital of Kunming Medical University, Department of Urology, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960); The 2nd Affiliated Hospital of Kunming Medical University, Department of Urology, Kunming, China (GRID:grid.415444.4) (ISNI:0000 0004 1800 0367)
2 The 1st Affiliated Hospital of Kunming Medical University, Department of Urology, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960); Yunnan Province Clinical Research Center for Chronic Kidney Disease, Kunming, China (GRID:grid.285847.4)
3 The Second People’s Hospital of Qujing City, Department of Urology, Qujing City, China (GRID:grid.285847.4)
4 The 1st Affiliated Hospital of Kunming Medical University, Department of Urology, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960)